Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.

Hall of Fame

Molecules of the Month

MOTY Nominees

Molecule of the Year

Join Subscribers From
Logos of companies subscribed
    Molecule
    Kymera's KT-474 is the first oral degrader to demonstrate activity in clinical trials outside cancer. Sanofi recently started a Ph. II trial with the molecule in AD, restoring life to IRAK4 as an immunology target. This article highlights several reasons why Kymera’s KT-474 program is scientifically notable, including but not limited to differentiation from small molecules, potential competitiveness with biologics, the first reported Cryo-EM ternary complex of a heterobifunctional degrader, and more. The molecule will likely be considered a modern “classic in drug discovery” for some time.
    Article
    In 2022, Turning Point Therapeutics ($TPTX) was acquired by BMS for a whopping $4.1 billion in cash. In November 2023, the most advanced molecule from Turning Point, repotrectinib, was approved for the treatment of ROS1+ NSCLC. This article explores the science behind repotrectinib, what made Turning Point so valuable, how we know, and what's next. [...]
    Molecule
    Chugai’s PCO371 is an oral, biased agonist and "molecular wedge" of the class B GPCR, PTHR1, that first entered development for hypoparathyroidism in 2015 (NCT02475616). While Class A GPCRs, which typically have compact ligandable pockets are the most common targets for approved drugs, Class B GPCRs like PTHR1, GLP-1R, and CGRP are notoriously difficult to drug since they normally bind large peptides with long transmembrane tunnels that are not easily bound by small molecules. This article explains what makes PCO371 a big deal for GPCR drug discovery.
    Article
    The team reviews hundreds of compounds from thousands of papers, press releases, and other sources each month to select candidates for Molecules of the Month. Here we have compiled a table of >70 additional molecules that were of interest in October 2023 but we did not have space for in MOTM. A few highlights are also discussed, including Novartis’s Werner helicase (WRN) inhibitor, APJ agonist AMG985 molecular glue degrader golcadomide, and more in the full article.
    Molecule
    TEAD1-4, nuclear transcription factors that are key effectors of the Hippo pathway, have become of increased recent interest in part due to the potential for TEAD inhibitors to synergize with RAS inhibition. GNE-7883, a pan-TEAD allosteric inhibitor tool from Genentech demonstrated in vivo proof-of-concept for combination therapy with a KRAS(G12C) inhibitor. This article highlights the rational design of an allosteric pan-TEAD inhibitor from a FRET-based HTS, the activities of GNE-7883 in YAP/TAZ-dependent cancers, and the potential applications of TEAD inhibitors in precision oncology.